Identification of Genes in Patients for Predicting Ulcerative Colitis-Associated Colorectal Cancer

CURRENT STATUS: UNDER REVIEW

BMC Medical Genomics

hongyun wei
affiliated hospital of qingdao university

qian zhang
affiliated hospital of qingdao university

xiaosa chi
affiliated hospital of qingdao university

xiaohui yang
affiliated hospital of qingdao university

zibin tian
affiliated hospital of qingdao university

linlin ren
affiliated hospital of Qingdao university

renlinlinqdfy@163.com Corresponding Author

DOI:
10.21203/rs.3.rs-24097/v1

SUBJECT AREAS
Epigenetics & Genomics

KEYWORDS
Bioinformatics analysis, Colorectal cancer, Prognosis, Ribosomes, Ulcerative colitis
Abstract

Background

Ulcerative colitis (UC) has been considered as a risk factor for colorectal cancer (CRC). However, effective biomarkers for predicting UC-associated CRC are lacking. Therefore, it is necessary to screen biomarkers associated with UC-related CRC, which could be used to evaluate UC-associated CRC early, and provide possible mechanisms involved in UC-associated CRC. Efficient bioinformatics analysis could help us to explore potential biomarkers.

Methods

Two public datasets, including 44 UC without CRC samples and 17 UC-associated CRC samples were chosen from Gene Expression Omnibus (GEO) database. Sva package was used to remove batch effects, and then we screened out differentially expressed genes (DEGs) with limma package. STRING and Cytoscape were used to achieve protein-protein interaction (PPI) network analysis. The survival curves between high and low gene expression were performed by log rank test based on the cancer genome atlas (TCGA) program. The expression of three identified hub genes was validated based on Oncomine. To validate the expression of three hub genes, we compared the expression of three hub genes between normal and colorectal cancer based on Oncomine.

Results

405 DEGs were identified, including 256 down-regulated genes and 149 up-regulated genes in UC-associated CRC tissues. 16 hub genes were identified. And among them, RPL6, RPL7, and RPL35 were related to poor prognosis of patients in survival analysis. Higher expression of RPL6, RPL7, and RPL35 was validated in CRC tissues based on Oncomine.

Conclusions

Our study showed that overexpressed RPL6, RPL7, and RPL 35 may be potential tumor oncogenes and could act as a prognostic factor in clinical diagnosis and treatment.

Background

Inflammatory bowel disease (IBD) is an immune dysfunction associated disease, which is a risk for colorectal cancer (CRC) according to guidelines from the European Crohn’s and Colitis Organization.
(ECCO)(1). However, the clinical symptoms of IBD-associated CRC are different from sporadic CRC, including diagnosis at younger age, location. In IBD-related CRC, the location is dominated in proximal colon, and the patients have mucinous or signet ring histopathologic character and poor prognosis(2,3). A recent meta-analysis showed that patients with ulcerative colitis (UC) have similar risk rate of CRC in Asia compared with Europe and North America, and no regional variation was found in Asia(4).

Recent study showed that IBD related CRC have some common causing factors with sporadic CRC, like environmental changes, microbiology changes. And IBD related CRC is more prone to be found in patients who are sedentary, consume imbalanced diet with low-fiber diet/higher red meat intake, and have lower vitamin D level, and excess emulsifier intake(5). An investigation to risk factors for UC-CRC patients in China showed that common risk factors between sporadic CRC and UC-CRC, such as higher onset age and long disease course was found in UC-CRC(6).

Endoscopy surveillance is still the main tool to assess UC associated CRC(7), however, there are still many limits, like invasive, the need of bowel preparation, long term examination, patient intolerance, and specialist training for chromoendoscopy(8). Furthermore, most of the patients with UC refused to endoscopically resect colitis associated dysplasia treatment(9), although it is an effective method. However, effective biomarkers for predicting UC-associated CRC are lacking. Therefore, it is necessary to screen IBD-CRC associated biomarkers, which could be used to early evaluate IBD-CRC, and provide possible mechanisms. In addition, the mechanisms involved in IBD associated CRC have not been clearly clarified yet, onset age and long term inflammatory status may be involved in IBD-CRC(10).

Inflammation has been regarded as a key factor contributing to IBD-CRC, and might promote cancer development via inducing DNA methylation mutation(11), and antibiotics could prevent colon epithelial cell proliferation by inhibiting DNA methylation and mutation(12). Runt-related transcription factor (RUNX) 3 was reported to loss activity in UC associated cancer(13), which might could be used for predict UC associated CRC. Otherwise, different miRNAs were found in tissues from UC, UC without neoplasia, UC patients with neoplasia. And miR193a was found to participate in the suppression of UC related CRC via regulating IL17RD/EGFR(14). IL23 was found highly expressed in UC and UC-CRC.
associated CRC. Na+/H + exchanger isoform 8 (NHE8) absence was reported to promote colitis associated CRC, which might be related to the increase of Wnt/β catenin activation and increase of Lgr5 expression in mice. In addition, intestinal microbiota were found to be involved in the development of IBD associated CRC in mouse model, like Bacteroides fragilis, histamine-producing Lactobacillus reuteri.

The specific mechanisms are still not clear, therefore, the prevention of IBD-associated CRC was based on anti-inflammation drugs, such as sulfasalazine, and 5-Aminosalicylic acid. Obviously, long-term use of drugs become a heavy burden for our society. Furthermore, most of the studies about the mechanisms involved in IBD associated CRC were based on animal model, which might be different from human being. Therefore, we screened different expressed molecules between sporadic CRC patients and UC-associated CRC patients based on public database gene expression omnibus (GEO), and aimed to find out biomarkers indicating the development of UC-associated CRC in patients with UC.

Methods

Microarray data. Two raw gene expression datasets [GSE37283, GSE3629] were downloaded from GEO public database. Two datasets were performed based on GPL13158 platform, Affymetrix Human Genome U 133 Plus PM Array Plate and GPL570, Affymetrix Human Genome U 133 Plus 2.0 Array, respectively. Microarray assay were conducted on RNA samples isolated from colon mucosa of the involved patients. 43 UC without cancer, and 6 UC-associated cancer were obtained from GSE3629 dataset, and 4 quiescent UC and 11 UC with neoplasia patients were from GSE37283. All the raw array data from the two above datasets were transferred to the gene expression matrix of the probe and merged via perl programming language, and then removed batch effects by performing background correction, quality control, and standardization through R package sva and limma.

Data processing and Recognition of DEGs. The DEGs of colon mucosa between UC without CRC patients and UC associated patients were screened out by R package limma. |log fold change| (|log FC|) > 4 and P < 0.001 were regarded having statistical significance. A heat map was built based on log2FC of the screened DEGs by R package pheatmap.
DEGs KEGG and GO enrichment analysis. To clarify the function of these differentially expressed genes, R package clusterProfiler is used to obtain Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional annotation information of these genes. P < 0.05 was chosen as cut-off value.

Protein-protein interact (PPI) network building. Search Tool for the Retrieval of Interacting Genes (STRING) (version10.5) database was used to construct PPI network. Figuring out the protein-protein functional interactions would help us to find possible mechanisms underlying the development of diseases, as described in previous study(29). In the current study, STRING database was used to construct PPI network of DEGs, and the combined score was set as more than 0.9. Then, we used Cytoscape (version 3.6.1) to construct protein-protein interaction networks. In addition, Molecular Complex Detection (MCODE) (version 1.5.1), as a plug-in of Cytoscape, was used to furthermore cluster dense areas in PPI network. MCODE scores was set as more than 5, the degree cut-off value was 2, the node score cut-off was set as 0.2, the Max depth was 100, and k-score was set as 2.

Hub genes identification, survival analysis and expression validation in Oncomine. The genes with degrees ≥ 25 were considered as hub genes. The biological process analysis of hub genes was carried out with Biological Networks Gene Oncology tool (BiNGO) (version 3.0.3). The survival curves between high and low gene expression were performed by log rank test based on TCGA program. The expression of three identified hub genes was validated based on Oncomine.

Statistical analysis
Quantitative data are shown as mean ± SEM. For quantitative data, t-test was used for statistical analysis. The analyses were performed with graphpad prism 8. Log rank test was used for survival analysis. P < 0.05 was considered statistically significant.

Results
Identification of DEGs. In total, 405 differentially expressed genes, including 149 up-regulated and 256 down-regulated, were identified, as shown in the volcano map (Fig. 1A). Furthermore, a heatmap was also used to visualize the top 120 DEGs according to |logFC| (Fig. 1B).

KEGG and GO enrichment analysis of DEGs. To further understand the function of identified DEGs,
functional and pathway enrichment analysis was carried out via R package clusterProfiler. For GO enrichment analysis, the DEGs were primarily involved in ‘structural constituent of ribosome’, ‘cell adhesion molecule binding’, ‘cadherin binding’, ‘amide binding’, ‘peptide binding’, ‘5S rRNA binding’, ‘cell adhesion mediator activity’, ‘cell-cell adhesion mediator activity’, and ‘enzyme inhibitor activity’ (Table 1; Fig. 2A). Moreover, for the KEGG pathway enrichment analysis, the DEGs were primarily enriched in ‘antigen processing and presentation’, ‘neuroactive ligand-receptor interaction’, ‘ribosome’, ‘cell adhesion molecules’, and ‘N-Glycan biosynthesis’ (Table 2; Fig. 2B).

| ID       | Description                                | P value   | p. adjust  | Count |
|----------|--------------------------------------------|-----------|------------|-------|
| GO:0003735 | structural constituent of ribosome         | 1.30E-20  | 7.82E-18   | 30    |
| GO:0045296 | cadherin binding                           | 9.71E-09  | 2.92E-06   | 25    |
| GO:0019843 | rRNA binding                               | 2.14E-08  | 4.29E-06   | 11    |
| GO:0050839 | cell adhesion molecule binding              | 2.09E-07  | 3.14E-05   | 29    |
| GO:0033218 | amide binding                              | 4.41E-06  | 0.000530631 | 20    |
| GO:0042277 | peptide binding                            | 1.08E-05  | 0.001082501 | 18    |
| GO:0008097 | 5S rRNA binding                            | 4.70E-05  | 0.004033996 | 4     |
| GO:0098631 | cell adhesion mediator activity             | 0.000134704| 0.010119638| 6     |
| GO:0004857 | enzyme inhibitor activity                   | 0.000161889| 0.010810554| 20    |
| GO:0098632 | cell-cell adhesion mediator activity        | 0.000349164| 0.020984734| 5     |
| GO:0098641 | cadherin binding involved in cell-cell adhesion | 0.000485991| 0.02630492  | 4     |
| GO:0008188 | neuropeptide receptor activity              | 0.000525223| 0.02630492  | 6     |
| GO:0004576 | oligosaccharyl transferase activity         | 0.000864826| 0.035044281| 3     |
| GO:0015467 | G-protein activated inward rectifier potassium channel activity | 0.000864826| 0.035044281| 3     |
| GO:0042923 | neuropeptide binding                       | 0.000874649| 0.035044281| 4     |
Table 2
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs

| ID     | Description                      | pvalue  | p.adjust | Count |
|--------|----------------------------------|---------|----------|-------|
| hsa03010 | Ribosome                         | 5.50E-19 | 1.17E-16 | 30    |
| hsa04612 | Antigen processing and presentation | 3.18E-06 | 0.000339 | 11    |
| hsa04080 | Neuroactive ligand-receptor interaction | 0.001702 | 0.120852 | 16    |
| hsa05012 | Parkinson disease                | 0.003138 | 0.167075 | 10    |
| hsa00510 | N-Glycan biosynthesis            | 0.007627 | 0.324903 | 5     |
| hsa05320 | Autoimmune thyroid disease       | 0.010585 | 0.355035 | 5     |
| hsa04932 | Non-alcoholic fatty liver disease | 0.01315  | 0.355035 | 9     |
| hsa04260 | Cardiac muscle contraction       | 0.013823 | 0.355035 | 6     |
| hsa05330 | Allograft rejection              | 0.015001 | 0.355035 | 4     |
| hsa05332 | Graft-versus-host disease        | 0.019414 | 0.372864 | 4     |
| hsa03060 | Protein export                   | 0.01948  | 0.372864 | 3     |
| hsa04915 | Estrogen signaling pathway       | 0.022699 | 0.372864 | 8     |
| hsa04940 | Type I diabetes mellitus         | 0.022757 | 0.372864 | 4     |
| hsa04514 | Cell adhesion molecules (CAMs)   | 0.029477 | 0.448468 | 8     |
| hsa04918 | Thyroid hormone synthesis        | 0.038985 | 0.522904 | 5     |

PPI network construction and Hub gene selection. The PPI network of DEGs consists of 133 nodes and 902 edges (Fig. 3A). The most significant module was gained from PPI network with 57 nodes and 729 edges (Fig. 3B). A top of 16 hub genes, all of which are up-regulated genes in patients with UC associated cancer according to the mcode score, were selected from the PPI network (Fig. 3C), including ribosomal protein L10α (RPL10A), ribosomal protein L18 (RPL18), ribosomal protein L19 (RPL19), ribosomal protein L23α (RPL23A), ribosomal protein L24 (RPL24), ribosomal protein L27 (RPL27), ribosomal protein L30 (RPL30), ribosomal protein L 34 (RPL34), ribosomal protein L 35 (RPL35), ribosomal protein L6 (RPL6), ribosomal protein L7 (RPL7), ribosomal protein L9 (RPL9), ribosomal protein S12 (RPS12), ribosomal protein S18 (RPS18), ribosomal protein S27α (RPS27A), ribosomal protein S5 (RPS5). Additionally, these hub genes were involved in ‘macromolecule biosynthetic process’, ‘macromolecule metabolic process’, ‘cellular metabolic process’, ‘protein metabolic process’, ‘gene expression’, and so on (Fig. 3D). To further evaluate the effect of those hub genes on survival of CRC patients, survival analysis was performed in those genes. Among them, RPL6, RPL7, and RPL35 were related to poor prognosis of patients. Patients with higher expression of RPL6, RPL7, and RPL35 had significantly poor overall survival rate compared to patients with lower expression level (P = 0.0127, 0.00876, and 0.00549, respectively) (Fig. 4A-C). In addition, we validate
the expression of the above three genes based on Oncomine database. RPL6 expression was significantly higher in colorectal carcinoma tissues than normal colon mucosa (p < 0.001) (Fig. 4D), and similar results were found in RPL35 and RPL7 expression based on Oncomine database (p < 0.001) (Fig. 4E-F).

Discussion
As we all known, UC is regarded as an independent factor of CRC. Hence, it’s necessary to clarify the molecular and pathological mechanisms participated in UC-associated CRC. And effective bioinformatics analysis could help us to reach this purpose, as well as avoiding wasting of resources. However, it is prone to higher false positive or negative rate based on one-single dataset analysis, and multi-center analysis could at some extent decrease this phenomenon. As a result, analysis based on two series from GEO datasets (GSE3629 and GSE37283) was performed in the current study to find out biomarkers indicating the process of UC-associated CRC. A total of 405 DEGs were identified, including 149 up-regulated and 256 down-regulated genes. To figure out the function of these DEGs, we performed KEGG and GO analysis. Functional analysis showed these DEGs were mainly involved in cell adhesion molecule binding. In addition, most of them were structural constituents of ribosome. Cell adhesion participates in a majority of physiological processes, for example, blood vessel endothelial cell-cell adhesion plays a key role in vascular integrity and barrier function, and controls the process of vasculogenesis, and angiogenesis(19), which is critical for the development of CRC(20).

Furthermore, 16 hub genes were screened via Cytoscape, including RPL10A, RPL18, ribosomal RPL19, RPL23A, RPL24, RPL27, RPL30, RPL34, RPL35, RPL6, RPL7, RPL9, RPS12, RPS18, RPS27A, and RPS5. All these hub genes are belonging to ribosomes, which are related to the development of various tumor types. The ribosomal protein gene 5 (RPL5) was reported to be significantly mutated in glioblastoma, melanoma and breast cancer samples as a haploinsufficient tumor suppressor(21). In addition, the expression of mitochondrial ribosome protein L35 (MRPL35) was found higher in colorectal cancer, and was associated with poor prognosis(22). Autophagy is considered as an important part in the development of CRC(23), and decreased expression of ribosomal protein S27 like (RPS27L) was found...
to induce autophagy in breast cancer via inactivating mTORC1(24). Interestingly, RPS27A was screened in the present study, indicating it might participate in the development of UC-CRC via autophagy. Besides, we also analyzed the correlation between these genes and prognosis. Overexpression of RPL6, RPL7 and RPL35 was found to be related to poor prognosis in patients with CRC, indicating the potential role of these three genes in the development of UC-CRC. To clarify the expression of these three genes, we analyzed the expression level of these hub genes in normal and colorectal cancer tissues base on Oncomine, and RPL6, RPL7 RPL35 were significantly high-expressed in CRC. In a recent study, RPL6 was identified via proteomic profiling, and was found significantly increased expression in human colorectal cancer tissue compared with adjacent normal tissue(25), which strongly supports our data. RPL35 of Bacillus subtilis was reported to play an essential role in cell proliferation and differentiation(26), suggesting its role in cancer cell proliferation. Interestingly, RPL35 was identified to predict pelvic lymph node metastasis in cervical carcinoma(27). Additionally, another study showed RPL7 was detected in the secretory granules of enterochromaffin cells, and was markedly increased in colorectal cancer cells(28), similar to the current finding. We demonstrated that the three genes may serve as potential markers for evaluating the development of UC-associated CRC.

Although we chose two datasets to perform analysis and aimed to avoid high false positive rate related to one single dataset analysis, there are still some limits in the current study. First, subgroup analysis based on disease degree, age and race is needed. Second, it is necessary to verify the effect of these genes on UC-CRC in large amounts of clinical sample. Last but not the least, imbalanced number of patients might affect the reliability of our results. Therefore, we verified our result in another database. Further studies are still needed to investigate the biological functions and understand the underlying molecular mechanism by which ribosomal proteins participate in UC-associated CRC.

Conclusions
Ribosomal proteins may play a crucial role during ulcerative colitis-related colorectal cancer. Among them, overexpressed RPL6, RPL7, and RPL 35 may be potential tumor oncogenes and have a strong
relationship with overall survival in CRC, and may act as a prognostic factor in clinical diagnosis and treatment. In the current study, three genes were identified in UC-associated CRC that may help clinicians in predicting and planning therapy for patients with UC-associated CRC.

Declarations

Ethics approval and consent to participate:
Not applicable.

Consent for publication:
Not applicable.

Availability of data and materials:
The datasets analyzed during the current study are available in the GEO and Oncomine repository.

Competing interests:
The authors declare that they have no competing interests.

Funding:
This work was supported by the National natural science foundation of China (NO. 81602056), the Shandong Provincial Natural Science Foundation, China (NO. ZR2016HQ45), and the Intramural Research Program of the Affiliated Hospital of Qingdao University [grant numbers 3091].

Authors’ Contribution:
WH drafted the paper, WHY, ZQ, CXS, YXH and RLL analyzed the data, WHY, ZQ and TZB collected the data. RLL designed the overall study and revised the manuscript. All authors reviewed the results and approved the final version of the manuscript.

Acknowledgments:
None.

References
1. Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, et al. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. Journal of Crohn's colitis. 2017;11(3):263–73.

2. Jewel Samadder N, Valentine JF, Guthery S, Singh H, Bernstein CN, Wan Y, et al. Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Digestive diseases sciences. 2017;62(8):2126–32.

3. Leowardi C, Schneider ML, Hinz U, Harnoss JM, Tarantino I, Lasitschka F, et al.
Prognosis of Ulcerative Colitis-Associated Colorectal Carcinoma Compared to Sporadic Colorectal Carcinoma: A Matched Pair Analysis. Ann Surg Oncol. 2016;23(3):870-6.

4. Bopanna S, Ananthakrishnan AN, Kedia S, Yajnik V, Ahuja V. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. The lancet Gastroenterology hepatology. 2017;2(4):269-76.

5. Al Bakir I, Curtius K, Graham TA. From Colitis to Cancer: An Evolutionary Trajectory That Merges Maths and Biology. Frontiers in immunology. 2018;9:2368.

6. Wu XR, Zheng XB, Huang Y, Cao Q, Zhang Hj, Miao YL, et al. Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study. Gastroenterology report. 2019;7(1):67-73.

7. Hata K, Anzai H, Ikeuchi H, Futami K, Fukushima K, Sugita A, et al. Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. Am J Gastroenterol. 2019;114(3):483-9.

8. Huguet JM, Suarez P, Ferrer-Barcelo L, Iranzo I, Sempere J. Screening for colorectal cancer in patients with inflammatory bowel disease. Should we already perform chromoendoscopy in all our patients? World journal of gastrointestinal endoscopy. 2018;10(11):322-5.

9. Yang DH, Rey I. Endoscopic Submucosal Dissection for Colitis-Associated Dysplasia. Clinical endoscopy. 2019;52(2):120-8.

10. Cohen-Mekelburg S, Schneider Y, Gold S, Ghosh G, Rosenblatt R, Hajifathalian K, et al. Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care. Digestive diseases sciences. 2019;64(8):2273-9.

11. Pekow J, Hernandez K, Meckel K, Deng Z, Haider Hl, Khalil A, et al. IBD-associated
Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. Journal of Crohn's colitis. 2019;13(7):884-93.

12. Hattori N, Niwa T, Ishida T, Kobayashi K, Imai T, Mori A, et al. Antibiotics suppress colon tumorigenesis through inhibition of aberrant DNA methylation in an azoxymethane and dextran sulfate sodium colitis model. Cancer Sci. 2019;110(1):147-56.

13. Shinagawa T, Hata K, Morikawa T, Matsunaga K, Emoto S, Murono K, et al. Loss of RUNX3 Immunoreactivity in Non-Neoplastic Rectal Mucosa May Predict the Occurrence of Ulcerative Colitis-Associated Colorectal Cancer. Digestion. 2019:1-9.

14. Pekow J, Meckel K, Dougherty U, Huang Y, Chen X, Almograbi A, et al. miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017;23(17):5281-91.

15. Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 2019;45:1-8.

16. Xu H, Li J, Chen H, Ghishan FK. NHE8 Deficiency Promotes Colitis-Associated Cancer in Mice via Expansion of Lgr5-Expressing Cells. Cellular molecular gastroenterology hepatology. 2019;7(1):19-31.

17. Lee YK, Mehrabian P, Boyajian S, Wu WL, Selicha J, Vonderfecht S, et al. The Protective Role of Bacteroides fragilis in a Murine Model of Colitis-Associated Colorectal Cancer. mSphere. 2018;3(6).

18. Shi Z, Fultz RS, Engevik MA, Gao C, Hall A, Major A, et al. Distinct roles of histamine H1- and H2-receptor signaling pathways in inflammation-associated colonic tumorigenesis. American journal of physiology Gastrointestinal liver physiology.
19. Schimmel L, Gordon E. The precise molecular signals that control endothelial cell-cell adhesion within the vessel wall. Biochemical Society transactions. 2018;46(6):1673-80.

20. Dickreuter E, Cordes N. The cancer cell adhesion resistome: mechanisms, targeting and translational approaches. Biological chemistry. 2017;398(7):721-35.

21. Fancello L, Kampen KR, Hofman IJ, Verbeeck J, De Keersmaecker K. The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types. Oncotarget. 2017;8(9):14462-78.

22. Zhang L, Lu P, Yan L, Yang L, Wang Y, Chen J, et al. MRPL35 Is Up-Regulated in Colorectal Cancer and Regulates Colorectal Cancer Cell Growth and Apoptosis. Am J Pathol. 2019;189(5):1105-20.

23. Mokarram P, Albokashy M, Zarghooni M, Moosavi MA, Sepehri Z, Chen QM, et al. New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy. 2017;13(5):781-819.

24. Xiong X, Liu X, Li H, He H, Sun Y, Zhao Y. Ribosomal protein S27-like regulates autophagy via the beta-TrCP-DEPTOR-mTORC1 axis. Cell death disease. 2018;9(11):1131.

25. Hammoudi A, Song F, Reed KR, Jenkins RE, Meniel VS, Watson AJ, et al. Proteomic profiling of a mouse model of acute intestinal Apc deletion leads to identification of potential novel biomarkers of human colorectal cancer (CRC). Biochem Biophys Res Commun. 2013;440(3):364-70.

26. Akanuma G, Nanamiya H, Natori Y, Yano K, Suzuki S, Omata S, et al. Inactivation of ribosomal protein genes in Bacillus subtilis reveals importance of each ribosomal protein for cell proliferation and cell differentiation. J Bacteriol. 2012;194(22):6282-
27. Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, et al. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer. 2011;117(15):3363–73.

28. Kasai H, Nadano D, Hidaka E, Higuchi K, Kawakubo M, Sato TA, et al. Differential expression of ribosomal proteins in human normal and neoplastic colorectum. The journal of histochemistry cytochemistry: official journal of the Histochemistry Society. 2003;51(5):567–74.

29. Zeng M, Liu J, Yang W, Zhang S, Liu F, Dong Z, et al. Identification of key biomarkers in diabetic nephropathy via bioinformatic analysis. Journal of cellular biochemistry. 2018.

Figures
DEGs identified in GSE3629 and GSE37283. A: Volcano plot of the distributions of all differentially expressed genes, mapping 149 upregulated genes (red dots) and 256 downregulated genes (green dots). No significantly changed genes are marked as black dots. B: Heatmap of the top 119 DEGs according to the value of $|\log FC|$. DEGs: differentially expressed genes.

Figure 2
Functional enrichment analysis of DEGs. A: GO analysis of DEGs. B: KEGG pathway analysis of DEGs. DEGs: differentially expressed genes. GO: Gene Ontology. KEGG: Kyoto Encyclopedia of Genes and Genomes.
PPI network and biological process analysis of the hub genes. (A) The PPI network of DEGs was built using Cytoscape. (B) The PPI network of most significant DEGs was built with plugin MCODE. (C) The PPI network of hub genes. (D) The biological process analysis of hub genes was constructed with BiNGO. The color gradation of nodes refers to the corrected P-value of ontologies. The nodes’ size refers to the numbers of genes involved in the ontologies. DEGs: differentially expressed genes. PPI: protein-protein interaction.
RPL6, RPL7, and RPL35 were identified as biomarkers and prognostic factors in CRC. (A-C) Survival analysis indicated that RPL6, RPL7, and RPL35 were poor prognosis factors in CRC. (D–F) Validation of RPL6, RPL7, and RPL35 expression from the Oncomine database. Higher expression of RPL6, RPL7, and RPL35 were found in CRC tissues compared with normal tissues (p<0.05). CRC: colorectal cancer.